KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).

Armin Attar, Seyed Alireza Mirhosseini, Anthony Mathur, Sheik Dowlut, Ahmad Monabati, Mohammad Kasaei, Firoozeh Abtahi, Yahya Kiwan, Massoud Vosough, Negar Azarpira

BMJ 391 e083382

PMID41224473
PMCIDPMC12570275
DOI10.1136/bmj-2024-083382
发表日期2025-11-12
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVE: To assess the effect of intracoronary infusion of mesenchymal stem cells on the development of post-myocardial infarction heart failure. DESIGN: Phase 3 randomised clinical trial. SETTING: Three tertiary hospitals in Shiraz, Iran. PARTICIPANTS: 420 patients with a first ST segment elevation acute myocardial infarction and left ventricular ejection fraction <40% were enrolled and randomised in a 1:2 ratio to receive intervention or standard care. INTERVENTION: Intracoronary infusion of allogenic Wharton's jelly derived mesenchymal stem cells within 3-7 days of acute myocardial infarction in addition to standard care. MAIN OUTCOME MEASURES: The primary endpoint was incidence of heart failure. Secondary endpoints included readmission to hospital for heart failure, all cause mortality, cardiovascular mortality, and readmission to hospital for myocardial infarction. Changes in left ventricular ejection fraction within six months post-myocardial infarction were compared between groups. RESULTS: A total of 396 patients (136 in the intervention group and 260 in the control group) were included in the final analysis, with a median follow-up of 33.2 months. Intracoronary infusion of mesenchymal stem cells had a preventive effect for incidence of heart failure (2.77 v 6.48 per 100 person years; hazard ratio 0.43, 95% confidence interval 0.21 to 0.89; P=0.024), readmission to hospital for heart failure (0.92 v 4.20 per 100 person years; 0.22, 0.06 to 0.74; P=0.015), and a composite endpoint of cardiovascular mortality and readmission for myocardial infarction or heart failure (2.80 v 7.16 per 100 person years; 0.39, 0.19 to 0.82; P=0.012). The intervention did not have a statistically significant effect on readmission to hospital for myocardial infarction (1.23 v 3.06 per 100 person years; hazard ratio 0.40, 0.14 to 1.19; P=0.10), all cause mortality (1.81 v 1.66 per 100 person years; 1.10, 0.40 to 3.02; P=0.86), or cardiovascular mortality (0.91 v 1.33 per 100 person years; 0.68, 0.18 to 2.57; P=0.57). Left ventricular ejection fraction in the intervention group showed a significantly greater improvement from baseline at six months compared with the control group (β=5.88, 95% confidence interval 4.00 to 7.76; P<0.001). CONCLUSIONS: Intracoronary infusion of Wharton's jelly derived mesenchymal stem cells significantly reduced the risk of incidence of heart failure, readmission to hospital for heart failure, and the composite endpoint of cardiovascular mortality and readmission to hospital for heart failure or myocardial infarction in patients after an acute myocardial infarction, suggesting that this technique may serve as a valuable adjunctive procedure after myocardial infarction to prevent the development of heart failure and reduce the risk of future adverse events. TRIAL REGISTRATION: ClinicalTrials.gov NCT05043610.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

Fig 2

Fig 2 Cumulative hazard estimates and log-rank test of PREVENT-TAHA8 trial’s endpoints: heart failure (HF) incidence (development) (primary endpoint), readmission to hospital for HF, all cause mortality, cardiovascular mortality, readmission to hospital for myocardial infarction (MI), and composite endpoint of cardiovascular mortality and readmission to hospital for HF or MI. An interactive version of this graphic and downloadable data are available at https://public.flourish.studio/visualisation/25452455/

Heart_failure_incidence_development_

heart failure incidence

Fig 2 · Panel Heart_failure_incidence_development_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Heart_failure_incidence_development_ 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump
查看结果
Readmission_to_hospital_for_heart_failure

readmission to hospital for heart failure

Fig 2 · Panel Readmission_to_hospital_for_heart_failure

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Readmission_to_hospital_for_heart_failure 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:off origin start曲线 2:extreme jump
查看结果
All_cause_mortality

all cause mortality

Fig 2 · Panel All_cause_mortality

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel All_cause_mortality 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条
查看结果
Cardiovascular_mortality

cardiovascular mortality

Fig 2 · Panel Cardiovascular_mortality

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Cardiovascular_mortality 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Readmission_to_hospital_for_myocardial_infarction

readmission to hospital for myocardial infarction

Fig 2 · Panel Readmission_to_hospital_for_myocardial_infarction

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Readmission_to_hospital_for_myocardial_infarction 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
Composite_endpoint_of_cardiovascular_mortality_and_readmission_to_hospital_for_myocardial_infarction_or_heart_failure

composite endpoint

Fig 2 · Panel Composite_endpoint_of_cardiovascular_mortality_and_readmission_to_hospital_for_myocardial_infarction_or_heart_failure

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Composite_endpoint_of_cardiovascular_mortality_and_readmission_to_hospital_for_myocardial_infarction_or_heart_failure 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 CONSORT diagram of patient flow in PREVENT-TAHA8 trial. IQR=interquartile range; LVEF=left ventricular ejection fraction; MI= myocardial infarction; WJ-MSC=Wharton’s jelly derived mesenchymal stem cells
非 KM Figure
Fig 3Fig 3 Crude and optimized Cox regression analysis for endpoints in PREVENT-TAHA8 trial. Top: crude hazard ratios from Cox regression analysis for trial endpoints. Bottom: optimised Cox regression models analysing treatment allocation and covariates for incidence of heart failure (HF) and readmission to hospital for HF. An interactive version of this graphic and downloadable data are available at https://public.flourish.studio/visualisation/25427034/
非 KM Figure
Fig 4Fig 4 Change in left ventricular ejection fraction (LVEF) at 6 month follow-up analysis. Top: box plot of baseline and 6 month LVEF. Bottom: Wilcoxon test results. Wilcoxon matched pairs signed rank test was used to assess differences between post-6 month LVEF and baseline LVEF within both intervention and control groups. To compare LVEF changes between treatment groups, Wilcoxon rank sum test was used
非 KM Figure
captionless-figurecaptionless-figure
非 KM Figure